(November 7, 2018, 10:42 AM EST) -- LOS ANGELES — A California state appeals court on Nov. 6 reversed summary judgment for three drug makers in the state’s coordinated incretin mimetic diabetes drug litigation, saying the trial court misapplied U.S. Supreme Court preemption case law about whether the Food and Drug Administration considered new evidence of risk (Aida Rotondo, et al. v. Amylin Pharmaceuticals, Inc., et al., No. B275314, Calif. App., 2nd Dist., Div. 7, 2018 Cal. App. Unpub. LEXIS 7515)....